Incyte Corporation vs Match Group Inc — how do they compare? Incyte Corporation trades at $120.45 (market cap $24.54B), while Match Group Inc trades at $37 (market cap $8.45B). The key difference: Incyte Corporation is far larger — about 2.9× Match Group Inc's market cap, and Match Group Inc pays a 2.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MTCH | |
|---|---|---|
Market Cap | $24.54B | $8.45B |
Sector | Health | Media |
52-Week High | $129.93 | $41.24 |
52-Week Low | $81.61 | $28.90 |
Enterprise Value | $20.04B | $11.42B |
Dividend Yield | — | 2.17% |
Trailing returns across standard periods
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →